3,965 Shares in CVS Health Co. (NYSE:CVS) Bought by Lesa Sroufe & Co

Lesa Sroufe & Co acquired a new position in CVS Health Co. (NYSE:CVS - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 3,965 shares of the pharmacy operator's stock, valued at approximately $269,000.

Other hedge funds have also recently made changes to their positions in the company. Dodge & Cox boosted its position in shares of CVS Health by 11.2% during the fourth quarter. Dodge & Cox now owns 70,105,899 shares of the pharmacy operator's stock worth $3,147,054,000 after acquiring an additional 7,075,209 shares during the last quarter. Capital World Investors boosted its stake in CVS Health by 26.6% during the fourth quarter. Capital World Investors now owns 61,039,777 shares of the pharmacy operator's stock valued at $2,739,927,000 after buying an additional 12,819,148 shares during the last quarter. Geode Capital Management LLC boosted its stake in CVS Health by 2.6% during the fourth quarter. Geode Capital Management LLC now owns 27,051,540 shares of the pharmacy operator's stock valued at $1,211,582,000 after buying an additional 689,867 shares during the last quarter. Capital International Investors boosted its position in shares of CVS Health by 4.8% during the 4th quarter. Capital International Investors now owns 26,666,401 shares of the pharmacy operator's stock valued at $1,196,989,000 after acquiring an additional 1,212,126 shares during the last quarter. Finally, Pzena Investment Management LLC lifted its position in CVS Health by 49.3% during the fourth quarter. Pzena Investment Management LLC now owns 19,610,579 shares of the pharmacy operator's stock valued at $880,319,000 after purchasing an additional 6,475,271 shares during the last quarter. Institutional investors own 80.66% of the company's stock.

CVS Health Trading Up 0.4%

Shares of NYSE CVS opened at $67.74 on Tuesday. The company has a quick ratio of 0.60, a current ratio of 0.81 and a debt-to-equity ratio of 0.80. The business has a fifty day simple moving average of $65.16 and a two-hundred day simple moving average of $60.21. The firm has a market cap of $85.69 billion, a PE ratio of 18.51, a price-to-earnings-growth ratio of 0.98 and a beta of 0.56. CVS Health Co. has a twelve month low of $43.56 and a twelve month high of $72.51.

CVS Health (NYSE:CVS - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 EPS for the quarter, beating the consensus estimate of $1.62 by $0.63. The business had revenue of $94.59 billion during the quarter, compared to analyst estimates of $93.07 billion. CVS Health had a net margin of 1.24% and a return on equity of 9.11%. The company's quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.31 EPS. Analysts expect that CVS Health Co. will post 5.89 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, May 1st. Stockholders of record on Tuesday, April 22nd were given a $0.665 dividend. This represents a $2.66 annualized dividend and a dividend yield of 3.93%. The ex-dividend date was Tuesday, April 22nd. CVS Health's payout ratio is 63.48%.

Analyst Ratings Changes

CVS has been the subject of a number of analyst reports. Barclays set a $79.00 price target on shares of CVS Health and gave the company an "overweight" rating in a report on Monday, June 2nd. UBS Group raised their price target on CVS Health from $67.00 to $71.00 and gave the stock a "neutral" rating in a research report on Friday, May 2nd. Cowen restated a "buy" rating on shares of CVS Health in a research report on Monday, May 5th. JPMorgan Chase & Co. raised their target price on shares of CVS Health from $80.00 to $81.00 and gave the stock an "overweight" rating in a report on Tuesday, February 18th. Finally, Truist Financial raised their price objective on shares of CVS Health from $82.00 to $84.00 and gave the stock a "buy" rating in a research note on Monday, May 12th. Two research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, CVS Health currently has an average rating of "Moderate Buy" and a consensus target price of $74.75.

Insider Transactions at CVS Health

In other news, Director Guy P. Sansone bought 1,570 shares of CVS Health stock in a transaction on Thursday, June 5th. The stock was acquired at an average cost of $63.70 per share, for a total transaction of $100,009.00. Following the completion of the acquisition, the director now owns 12,007 shares of the company's stock, valued at $764,845.90. This trade represents a 15.04% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.22% of the company's stock.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Co. (NYSE:CVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.